Drug Information

Drug (ID: DG01681) and It's Reported Resistant Information

• Name: PI3K pathway inhibitors/MEK inhibitors
• Synonyms: PI3K pathway inhibitors/MEK inhibitors
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Receptor tyrosine-protein kinase erbB-3 (ERBB3) [1]

• Molecule Alteration: Missense mutation; p.Q809R (c.2426A>G)
• Sensitive Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: DNA sequencing assay
• Mechanism Description: The missense mutation p.Q809R (c.2426A>G) in gene ERBB3 cause the sensitivity of PI3K pathway inhibitors + MEK inhibitors by unusual activation of pro-survival pathway

Key Molecule: Receptor tyrosine-protein kinase erbB-3 (ERBB3) [1]

• Molecule Alteration: Missense mutation; p.P262H (c.785C>A)
• Sensitive Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: DNA sequencing assay
• Mechanism Description: The missense mutation p.P262H (c.785C>A) in gene ERBB3 cause the sensitivity of PI3K pathway inhibitors + MEK inhibitors by unusual activation of pro-survival pathway

Key Molecule: Receptor tyrosine-protein kinase erbB-3 (ERBB3) [1]

• Molecule Alteration: Missense mutation; p.G284R (c.850G>A)
• Sensitive Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: DNA sequencing assay
• Mechanism Description: The missense mutation p.G284R (c.850G>A) in gene ERBB3 cause the sensitivity of PI3K pathway inhibitors + MEK inhibitors by unusual activation of pro-survival pathway

Key Molecule: Receptor tyrosine-protein kinase erbB-3 (ERBB3) [1]

• Molecule Alteration: Missense mutation; p.Q809R (c.2426A>G)
• Sensitive Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: DNA sequencing assay
• Mechanism Description: The missense mutation p.Q809R (c.2426A>G) in gene ERBB3 cause the sensitivity of PI3K pathway inhibitors + MEK inhibitors by unusual activation of pro-survival pathway

Key Molecule: Receptor tyrosine-protein kinase erbB-3 (ERBB3) [1]

• Molecule Alteration: Missense mutation; p.P262H (c.785C>A)
• Sensitive Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: DNA sequencing assay
• Mechanism Description: The missense mutation p.P262H (c.785C>A) in gene ERBB3 cause the sensitivity of PI3K pathway inhibitors + MEK inhibitors by unusual activation of pro-survival pathway

Key Molecule: Receptor tyrosine-protein kinase erbB-3 (ERBB3) [1]

• Molecule Alteration: Missense mutation; p.G284R (c.850G>A)
• Sensitive Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: DNA sequencing assay
• Mechanism Description: The missense mutation p.G284R (c.850G>A) in gene ERBB3 cause the sensitivity of PI3K pathway inhibitors + MEK inhibitors by unusual activation of pro-survival pathway

References

• Ref 1: Oncogenic ERBB3 mutations in human cancersCancer Cell. 2013 May 13;23(5):603-17. doi: 10.1016/j.ccr.2013.04.012.